Fabrizio Galimberti, Ph.D.
Affiliations: | 2011 | Pharmacology and Toxicology | Dartmouth College, Hanover, NH, United States |
Area:
Molecular Biology, OncologyGoogle:
"Fabrizio Galimberti"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Ethan Dmitrovsky | grad student | 2011 | Dartmouth | |
| (Transgenic Cyclin E Murine Models as Discovery Tools for Lung Cancer Biology, Therapy, and Prevention.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Soler DC, Young AB, Fiessinger L, et al. (2016) Increased, but functionally impaired, CD14(+) HLA-DR(neg/low) Myeloid-Derived Suppressor Cells in psoriasis; a mechanism of dysregulated T cells. The Journal of Investigative Dermatology |
| Galimberti F, Fernandez AP. (2016) Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: a rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis? Clinical and Experimental Dermatology. 41: 413-6 |
| Hu S, Danilov AV, Godek K, et al. (2015) CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Research. 75: 2029-38 |
| Busch AM, Galimberti F, Nehls KE, et al. (2014) All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Cancer Biology & Therapy. 15: 463-72 |
| Hu S, Danilov AV, Godek KM, et al. (2014) Abstract 4549: CDK2 inhibition causes anaphase catastrophe through the centrosomal protein CP110 Cancer Research. 74: 4549-4549 |
| Ma T, Galimberti F, Erkmen CP, et al. (2013) Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Molecular Cancer Therapeutics. 12: 1545-55 |
| Rodriguez-Blanco J, Schilling NS, Tokhunts R, et al. (2013) The hedgehog processing pathway is required for NSCLC growth and survival. Oncogene. 32: 2335-45 |
| Dragnev K, Beumer J, Anyang B, et al. (2013) A Proof-of-Principle Histone Deacetylase Inhibitor Trial in Resectable Aerodigestive Tract Cancer: Intratumoral Drug Levels and Biomarker Responses Annals of Oncology. 24: i7 |
| Galimberti F, Busch AM, Chinyengetere F, et al. (2012) Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. International Journal of Oncology. 41: 1751-61 |
| Guo Y, Chinyengetere F, Dolinko AV, et al. (2012) Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Molecular Cancer Therapeutics. 11: 1968-77 |